Newton BioCapital in €15.3m series-B for Acticor

Other backers in the round included Mirae Capital, a Korean fund, along with Hong Kong-based CMS Medical Venture Investment Limited and A&B (HK). Existing investors including CapDecisif Management also participated into this round.

Additionally, the series-B could be expanded by up to €5m in order to finance additional clinical developments.

Alain Parthoens, managing director of Newton BioCapital, will join the board of directors.

Previous funding
CapDecisif Management invested €1.5m in Acticor Biotech in 2017. Primer Capital then invested €1.7m alongside some existing investors in the company in January 2018. Primer Capital investment partner Timur Avdeenko was appointed as an observer on the Acticor Biotech board. Previous backers Anaxago and CapDecisif Management, as well as private investors, also committed to the round.
 
Company
Acticor Biotech is a biopharmaceutical company founded in 2013 as a spinoff from Inserm. The clinical-stage biotechnology company is involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism. Acticor is headquartered in Paris.

People
Newton Biocapital – Alain Parthoens (managing director).
Acticor Biotech - Gilles Avenard (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Benelux
• Venture